Ginkgo Bioworks Holdings, Inc. - 8-K Filing
Ginkgo Bioworks reported Q1 2026 revenue of $19 million, a 49% decrease from $38 million in the same period last year, primarily due to program rationalization and the divestiture of its Biosecurity business completed on April 3, 2026. GAAP net loss from continuing operations was $76 million, compared to $83 million in Q1 2025, while Adjusted EBITDA was -$42 million, down from -$44 million. The company reaffirmed its 2026 cash burn guidance of -$150 to -$125 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $DNA